Drug Profile
Research programme: mitochondrial protein modulators - Epirium Bio
Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Cardero Therapeutics
- Developer Epirium Bio; Sphaera Pharma
- Class Small molecules
- Mechanism of Action Mitochondrial protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cerebrovascular disorders; Metabolic disorders; Neuromuscular disorders
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Neuromuscular-disorders in USA
- 25 Feb 2020 Preclinical trials in Neuromuscular disorders in USA (unspecified route)
- 25 Feb 2020 Epirium Bio plans a clinical trial for Duchenne muscular dystrophy (Becker Muscular Dystrophy) in 2021